1 2

3

5

7

9

10 11

12

14

13

1516

18 19

17

20

222324

2425

A bill to be entitled

An act relating to public meetings and public records; amending s. 381.02033, F.S.; exempting from public meeting requirements specified portions of meetings of the Prescription Drug Affordability Commission; exempting from public records requirements specified records, transcripts, and information; requiring the commission to establish certain parameters; providing for future legislative review and repeal of the exemptions; providing statements of public necessity; providing a contingent effective date.

Be It Enacted by the Legislature of the State of Florida:

- Section 1. Paragraph (c) of subsection (3) and subsection (9) of section 381.02033, Florida Statutes, as created by HB 1293, 2020 Regular Session, are amended to read:
 - 381.02033 Prescription Drug Affordability Commission.-
- (3) MEETINGS OF THE COMMISSION.—The commission shall meet in a location readily accessible to the public at least every 6 weeks to review prescription drug price notices submitted under subsection (4). A meeting may be cancelled or postponed at the discretion of the chair if there is no pending decision.
- (c) The commission may allow expert testimony at a public meeting.

Page 1 of 5

CODING: Words stricken are deletions; words underlined are additions.

1. Any decision that the commission makes must be done in a public meeting, including, but not limited to, the following decisions:

a.1. Reviewing a prescription drug cost analysis.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

4950

- $\underline{\text{b.2.}}$ Voting on whether to impose a cost or payment limit on payors for a prescription drug.
- 2.a. However, any portion of a meeting in which prescription drug information that the commission designates a trade secret is discussed is exempt from s. 286.011 and s. 24(b), Art. I of the State Constitution. Any records generated by such portion of a meeting, except the final recommendations or votes, are confidential and exempt from s. 119.07(1) and s. 24(a), Art. I of the State Constitution. The commission shall establish parameters for what is designated a trade secret, including, but not limited to, specific consideration for information submitted relating to a prescription drug not yet available in the market.
- b. This subparagraph is subject to the Open Government
 Sunset Review Act in accordance with s. 119.15 and shall stand
 repealed on October 2, 2025, unless reviewed and saved from
 repeal through reenactment by the Legislature.
 - (9) PUBLIC ACCESS TO INFORMATION.-
- (a) Information relating to a prescription drug price notice submitted by a prescription drug manufacturer to the commission or relating to a prescription drug cost review is

Page 2 of 5

CODING: Words stricken are deletions; words underlined are additions.

available to the public.

(b) However, any information relating to a prescription drug price notice submitted by a prescription drug manufacturer or relating to a prescription drug cost review that is designated by the commission as a trade secret is confidential and exempt from s. 119.07(1) and s. 24(a), Art. I of the State Constitution. This paragraph is subject to the Open Government Sunset Review Act in accordance with s. 119.15 and shall stand repealed October 2, 2025, unless reviewed and saved from repeal through reenactment by the Legislature.

Section 2. (1) The Legislature finds that it is a public necessity that a trade secret, as defined in s. 688.002, Florida Statutes, that is used in manufacturing a prescription drug and that is provided in a prescription drug price notice by a manufacturer to the Prescription Drug Affordability Commission, established in s. 381.02033, Florida Statutes, be made confidential and exempt from public meeting and public records requirements.

(2) In general, a prescription drug manufacturer invests substantial economic resources in chemically developing a prescription drug. Disclosing a prescription drug trade secret would allow competitor companies to gain an unfair competitive advantage, thereby negatively impacting the business interest of the prescription drug manufacturer. Even though reliable reporting of prescription drug pricing models and price

increases is necessary to ensure that prices and price changes for prescription drugs meet the commission's determination that such prices are affordable to consumers, the goal of prescription drug affordability is best served by encouraging prescription drug manufacturers to submit pricing models and price increases to the commission for review without concern that trade secrets will be disclosed through public meetings or public records requests.

- (3) The release of a prescription drug trade secret via a public meeting would allow competitors and other persons who attend those meetings to discover the protected trade secrets.

 Likewise, a release of the records generated during those portions of a meeting at which trade secrets are discussed would compromise such proprietary information.
- (4) Therefore, the Legislature finds that it is a public necessity to make any portion of a meeting in which a prescription drug trade secret is discussed exempt from public meeting requirements and to make records and transcripts thereof exempt from public records requirements. The Legislature also finds that it is a public necessity to make any information relating to a prescription drug price notice submitted by a prescription drug manufacturer or relating to a prescription drug cost review that is designated by the commission as a trade secret confidential and exempt from public records requirements.

Page 4 of 5

Section 3. This act shall take effect on the same date

that HB 1293 or similar legislation takes effect, if such legislation is adopted in the same legislative session or an extension thereof and becomes a law.

Page 5 of 5

CODING: Words stricken are deletions; words underlined are additions.